Neurocrine Biosciences (NBIX) Exchange Rate Effect (2023 - 2025)
Neurocrine Biosciences' (NBIX) quarterly Exchange Rate Effect came in at -$200000.0 in Q3 2025, down 166.67% on a YoY basis from $300000.0 in Q3 2024, and up 33.33% quarter-over-quarter from -$300000.0 in Q4 2024.
Analysis
Neurocrine Biosciences (NBIX) Exchange Rate Effect (2023 - 2025) Analysis & Trends
Neurocrine Biosciences (NBIX) has reported Exchange Rate Effect for 3 consecutive years, with -$200000.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Exchange Rate Effect fell 166.67% year-over-year to -$200000.0; the trailing twelve-month figure through Dec 2025 stood at -$200000.0 (changed N/A YoY), and the FY2023 full-year result was $300000.0, up 123.08% from the prior year.
- Exchange Rate Effect advanced to -$200000.0 in Q3 2025 per NBIX's latest filing, from -$300000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $300000.0 in Q4 2023 and bottomed at -$300000.0 in Q4 2024.
- Historically, Exchange Rate Effect has averaged $25000.0 across 3 years, with a median of $50000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect slumped 200.0% in 2024, then sank 166.67% in 2025.
- Over 3 years, Exchange Rate Effect stood at $300000.0 in 2023, then plunged by 200.0% to -$300000.0 in 2024, then soared by 33.33% to -$200000.0 in 2025.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$200000.0, -$300000.0, and $300000.0 for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | -4.00 Mn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | 11.62 Mn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | -84,000.00 |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -200,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |